HGS discontinues repifermin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Human Genome Sciences ceases development of repifermin, the firm announces Feb. 2. The keratinocyte growth factor was not statistically different from placebo in a Phase II study in cancer therapy-induced mucositis. "No other clinical trials of repifermin are underway or planned in any indication"...